Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Novartis

Swiss multinational pharmaceutical company

Novartis    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Novartis: Swiss multinational pharmaceutical company
Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies by both market capitalization and sales.

0
shares
ShareTweetSavePostSend
 

Novartis now has the most expensive drug ever after getting US approval

novartis now has the most expensive drug ever after getting us approval
Swiss pharmaceutical company Novartis on Friday announced it had received US regulatory approval for a gene therapy that treats a rare childhood disorder and has a price tag of $2.1 million, making it..
WorldNews - Published

Novartis $2 million gene therapy for rare disorder is world's most expensive drug

ZURICH/NEW YORK - Swiss drugmaker Novartis on Friday won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, and priced the..
Reuters - Published

Videos for Novartis

FDA Approves $2.125 Million Gene Therapy From Novartis [Video]FDA Approves $2.125 Million Gene Therapy From Novartis

Reuters reports that the Swiss drugmaker Novartis has secured U.S. approval for its gene therapy "Zolgensma". The therapy is used to treat spinal muscular atrophy (SMA). which is the leading genetic..

Credit: Wochit News     Duration: 00:31Published

The FDA Approves New Treatment For Devastating Disease And It Will Cost A Fortune [Video]The FDA Approves New Treatment For Devastating Disease And It Will Cost A Fortune

The US FDA just approved a new treatment for a devastating rare genetic disease. Called Zolgensma, it is a type of cutting-edge, one-time treatment called a "gene therapy" that treats the disease..

Credit: Wochit News     Duration: 00:49Published

 

This New Treatment Could Save the Lives of Babies. But It Costs $2.1 Million.

The price set by the Swiss drugmaker Novartis may be the world’s highest for a single treatment — prompting renewed debate about how society will pay for gene-therapy breakthroughs.
NYTimes.com - Published

U.S. approves $2 million Novartis gene therapy for rare, deadly muscle disorder

ZURICH/NEW YORK - Swiss drugmaker Novartis won U.S. approval for its gene therapy Zolgensma for spinal muscular atrophy (SMA), the leading genetic cause of death in infants, the company said on Friday,..
Reuters - Published

Search this site and the web:

You Might Like


Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.